-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda Pharmaceutical Announces Phase 3 Trial Results for Ovevorexton (TAK-861) in Narcolepsy Type 1 Ahead of World Sleep 2025 Congress

Reuters·07/31/2025 04:07:39

Please log in to view news